Repligen
RGEN
S$161.33
Share price
4.72%
Change (1 day)
-12.88%
Change (1 year)
Categories
Revenue for Repligen (RGEN)
Revenue in 2025 (TTM): S$0.86 Billion
According to Repligen
's latest financial reports the company's current revenue (TTM 
) is S$0.83 Billion. In 2024 the company made a revenue of S$0.86 Billion an increase over the revenue in the year 2023 that were of S$0.82 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Repligen from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | S$0.86 B | 0.79% |
| 2024 | S$0.86 B | 5.07% |
| 2023 | S$0.82 B | -23.61% |
| 2022 | S$1.07 B | 18.54% |
| 2021 | S$0.90 B | 87.08% |
| 2020 | S$0.48 B | 32.99% |
| 2019 | S$0.36 B | 37.45% |
| 2018 | S$0.26 B | 40.32% |
| 2017 | S$0.18 B | 24.85% |
| 2016 | S$0.15 B | 28.04% |
| 2015 | S$0.11 B | 40.72% |
| 2014 | S$83.96 M | -2.78% |
| 2013 | S$86.36 M | 13.43% |
| 2012 | S$76.14 M | |
| 2010 | S$33.82 M | 16.43% |
| 2009 | S$29.05 M | -27.63% |
| 2008 | S$40.14 M | 41.64% |
| 2007 | S$28.34 M | 39.37% |
| 2006 | S$20.33 M | -6.21% |
| 2005 | S$21.67 M | 56.72% |
| 2004 | S$13.83 M | 18.88% |
| 2003 | S$11.63 M | -7.46% |
| 2002 | S$12.57 M | 87.06% |
| 2001 | S$6.72 M | 44.85% |
| 2000 | S$4.64 M | -19.02% |
| 1999 | S$5.73 M | 44.62% |
| 1998 | S$3.96 M | -18.96% |
| 1997 | S$4.88 M | -8.06% |
| 1996 | S$5.31 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Novavax NVAX | S$1.56 B | 86.74% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | S$3.79 B | 353.58% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | S$3.10 B | 270.92% | 🇺🇸 USA |
 General Electric GE | S$51.08 B | 6,000.59% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | S$55.23 B | 6,495.34% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$61.33 B | 7,223.78% | 🇺🇸 USA |
 Pfizer PFE | S$80.42 B | 9,503.35% | 🇺🇸 USA |
 Bio-Techne TECH | S$1.55 B | 85.84% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | S$82.08 M | -90.20% | 🇺🇸 USA |
 Charles River Laboratories
CRL | S$5.17 B | 518.45% | 🇺🇸 USA |